WS #11713

From 500 msgs · 8 key-dev

Dr. Reddy's shares fell 7% after delaying commercial launch of semaglutide due to API quality issue, with supply halted until late October. PepsiCo reported Q2 revenue beat ($24.18B vs $23.96B est) but North America food revenue declined 2% organically, with management noting gradual improvement.

Dr. Reddy's Semaglutide Delay

Dr. Reddy's shares fell 7% after delaying commercial launch of semaglutide due to API quality issue, with supply halted until late October.

PepsiCo reported Q2 revenue beat ($24.18B vs $23.96B est) but North America food revenue declined 2% organically, with management noting gradual improvement.

Full world state #11713 →